Natera is trading at $320.18, down 14.20%, after its $0.42-per-share quarterly loss missed analysts’ $0.27 estimate.
- November 5 results showed $794 million in quarterly revenue; higher research, commercial, and pharma investment spending contributed to the shortfall.
- Natera raised its 2026 revenue outlook, but reports say the earnings miss overshadowed that positive news.
- CEO Steve Chapman’s departure and Solomon Moshkevich’s appointment added uncertainty; broader biotech weakness may add pressure.